Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell 1.7% during trading on Thursday . The stock traded as low as $2.35 and last traded at $2.36, with a volume of 54,382 shares changing hands. The stock had previously closed at $2.40.

Separately, Maxim Group set a $5.00 price objective on shares of BrainStorm Cell Therapeutics and gave the company a “buy” rating in a research note on Thursday.

The stock’s 50-day moving average price is $2.52 and its 200 day moving average price is $2.42. The firm’s market cap is $44.21 million.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Thursday, August 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.13. Equities analysts predict that BrainStorm Cell Therapeutics Inc. will post ($0.34) EPS for the current year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.